{Reference Type}: Journal Article
{Title}: Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.
{Author}: Nandakumar B;Kumar SK;Dispenzieri A;Buadi FK;Dingli D;Lacy MQ;Hayman SR;Kapoor P;Leung N;Fonder A;Hobbs M;Hwa YL;Muchtar E;Warsame R;Kourelis TV;Russell S;Lust JA;Lin Y;Go RS;Siddiqui M;Zeldenrust S;Kyle RA;Gertz MA;Rajkumar SV;Gonsalves WI;
{Journal}: Clin Lymphoma Myeloma Leuk
{Volume}: 20
{Issue}: 1
{Year}: 01 2020
{Factor}: 2.822
{DOI}: 10.1016/j.clml.2019.09.624
{Abstract}: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical and cytogenetic features of NSMM in this study.<BR>This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester, MN, between 2008 and 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.<BR>These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70% and more than one-half of all patients having Multiple Myeloma International Staging System Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort, accounting for more than 50% of the cohort. Finally, the overall survival of this cohort appears to be slightly worse than a matched-control group of newly diagnosed patients with MM with secretory disease.<BR>Future multi-institution studies confirming these above findings on this rare entity are warranted.